Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada-based Cipher Pharmaceuticals has entered into a definitive distribution and supply agreement with Laboratorios Andrómaco (Andrómaco) for isotretinoin product in Chile.
Subscribe to our email newsletter
Under the deal, Cipher has granted Andrómaco the exclusive right to market, sell and distribute its isotretinoin capsules in the country.
After securing regulatory approval, it is expected that Cipher’s product will be marketed under the brand name Lisacne-CIP, replacing Andrómaco’s existing isotretinoin product, Lisacne.
In Chile, Andrómaco currently markets branded dermatology products such as Fucidin and Daivonex.
Cipher Pharmaceuticals president and chief executive officer Larry Andrews said, "Extending the reach of our isotretinoin product is one of our growth priorities, and we believe Andrómaco is an excellent partner to bring this product to market in Chile."
Cipher’s isotretinoin capsules are a patent-protected formulation of isotretinoin, which is used to treat severe recalcitrant nodular acne.
Isotretinoin capsules are marketed in the US as Absorica and in Canada as Epuris.
As part of the deal, Cipher will supply product to Andrómaco, which is majority owned by Grünenthal, while product manufacturing will be carried out by Cipher’s partner, Galephar Pharmaceutical Research.